TABLE 1.
Patient Characteristics
| BEST: TI n = 46 | BEST: TE n = 52 | P value (BEST-TE vs BEST-TI) | DAWN (untreated) n = 99 | DEFUSE-3 (untreated) n = 90 | P value (BEST-TI vs DAWN) | P value (BEST-TI vs DEFUSE-3) | |
|---|---|---|---|---|---|---|---|
| Age, mean (SD) or median (IQR) | 66 (58-77) | 71 (53-82) | .69 | 70.7 (13.2) | 71 (59-80) | – | – |
| No. female (%) | 19 (41%) | 25 (48%) | 50 | 48 (48%) | 46 (51%) | .43 | .27 |
| Race, no. (%) | .08 | n/a | – | ||||
| Black | 7 (15%) | 12 (23%) | NR | 5 (6%) | |||
| Caucasian | 25 (54%) | 22 (42%) | NR | 80 (89%) | |||
| Asian | 2 (4%) | 0 (0%) | NR | 3 (3%) | |||
| Other/unknown | 12 (26%) | 18 (35%) | NR | 2 (2%) | |||
| Time from last seen normal to EVT, median min (IQR) | 733 (550-990) | 725 (595-973) | .90 | NR | NR | n/a | n/a |
| Baseline NIHSS, median (IQR) | 12 (7-18) | 18 (13-21) | <.01 | 17 (14-21) | 16 (12-21) | ||
| LVO location | – | – | |||||
| ICA-T | 12 (26%) | 16 (31%) | .61 | 19 (19%) | 36 (40%) | .34 | .11 |
| M1 | 15 (33%) | 41 (79%) | <.01 | 78 (77%) | 54 (60%) | <.01 | <.01 |
| M2 | 19 (41%) | 0 (0%) | <.01 | 3 (3%) | 0 (0%) | <.01 | <.01 |
| ASPECTS, median (IQR) | 7 (5-9) | 8 (7-9) | .06 | NR | 8 (7-9) | n/a | – |
| Volume of ischemic core, median rCBF <30% mL (IQR) | 15 (0-49) | 6 (0-20) | .07 | 8.9 (3.0-18.1) | 10.1 (2.1-24.3) | ||
| Volume of perfusion deficit, median Tmax >6 s mL (IQR) | 101 (55-167) | 121 (66-157) | .57 | NR | 116.1 (73.4-158.2) | n/a | – |
| Treatment with IV tPA | 4 (9%) | 4 (8%) | 1.00 | 13 (13%) | 8 (9%) | .49 | 1.00 |
NR, TI, trial-ineligible; TE, trial-eligible; SD, standard deviation; IQR, interquartile range; EVT, endovascular thrombectomy; NIHSS, National Institutes of Health Stroke Scale; LVO, large vessel occlusion; ICA-T, internal carotid artery terminus; ASPECTS, Alberta Stroke Program Early Computed Tomography Score; IV tPA, intravenous tissue plasminogen activator.